TCB-005

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameTCB-005
Drug Alias NameB7-H3 CAR-T therapy TCB-005allogeneic CAR-T cell therapy TCB-005Anti-B7-H3 Car-T therapy TCB-005B7-H3 chimeric antigen receptor γδ T cell therapyAnti-B7-H3 gamma delta CAR-T cell therapy (Tc Biopharm) +[10] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Chimeric antigen receptor γδT cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy > Chimeric antigen receptor γδT cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-CD276
TargetsCD276 antigen
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTc Biopharm Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTc Biopharm Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A